University of Kansas Cancer Center Post San Antonio Review


 

48 y/o PALB2 Mutation Carrier With T2N0 ER/PR+, HER2- BC: How to Counsel This Patient? What Treatment to Recommend in the Metastatic Setting?

273 views
February 28, 2021
0 Comments
Login to view comments. Click here to Login